
    
      Prior to initiation of this study, global Phase 2b study and pivotal Phase III studies were
      completed in the Western countries and market authorization of adalimumab was approved in
      United States (US) and European Union (EU) for the treatment of subjects with HS. The
      differences between this study and global studies include sample size, study design,
      duration, and race.
    
  